New drugs in acute myeloid leukemia.
New drugs in acute myeloid leukemia.
复制标题
DOI：
10.1007/s11912-002-0029-8
复制
发表时间：
2002-09-01
影响因子：
4.7
通讯作者：
Giles, Francis J
中科院分区：
文献类型：
--
作者：
Giles, Francis J
急性髓系白血病（AML）通常是致命的疾病，具有一系列临床、形态学、细胞遗传学和分子特征，因此需要多样化的治疗。急性早幼粒细胞白血病患者需要量身定制的治疗，这在本期的另一篇文章（Tallman和Nabhan）中有很好的体现。不幸的是，我们倾向于在非常晚期的疾病患者中检查新药物，其中先前的治疗不可避免地改变了肿瘤。无数的可能令人兴奋的新的代理商，一些，包括PS-341，Genasense（Genta，伯克利高地，新泽西州），地西他滨，5-氮杂胞苷，氯法拉滨，和曲沙他滨，简要回顾了从一个角度，建议可能的协同治疗干预的作用机制的重点。随着对AML中血管生成的关键作用的日益认识，血管生成调节剂是一个很好的核心药物类别的例子，未来的非细胞毒性组合可能会建立在此基础上。对血管内皮生长因子靶向药物的研究进展也作了简要综述。
The acute myeloid leukemias (AML) are often fatal disorders with a range of clinical, morphologic, cytogenetic, and molecular features and a consequent need for a diverse array of therapies. This need for tailored therapy for subsets of patients with AML is exemplified in those with acute promyelocytic leukemia, the subject of a separate article in this issue (Tallman and Nabhan). Unfortunately, we tend to examine novel agents in patients with very advanced disease, in which prior therapies have inevitably altered the tumor. Of a myriad of possible exciting novel agents, a few, including PS-341, Genasense (Genta, Berkeley Heights, NJ), decitabine, 5-azacytidine, clofarabine, and troxacitabine, are briefly reviewed with an emphasis on their mechanisms of action from a perspective that suggests possible synergistic therapeutic interventions. With the growing appreciation of the pivotal role of angiogenesis in AML, angiogenesis modulators are a good example of a core class of drugs upon which future noncytotoxic combinations may be built. Those agents targeting vascular endothelial growth factor are also briefly reviewed.